Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai, Pune, and Bangalore. Our main focus was a visit with a major client, a CDMO with multiple facilities across the country. Here are a few
Last week, Sandoz announced they are closing a number of generic product development centers around the world, including the Sandoz Development Centre near Mumbai. A few items in this report caught our eye. First, this hat tip to the CRO industry: While a pharma industry expert said the closure of the development centre would mean
There is a fascinating discussion taking place over at Derek Lowe’s blog today on one-man drug companies: …some of them are not quite down to one person, but you can count the employees on your fingers. In all of these cases, everything is being contracted out. Aside from the samples given in the post, and
Today’s In Vivo Blog post summarizes comments that we have been hearing from our clients as well. Namely, that deals are increasingly shifting towards back-ended Royalties and earn-outs, at the expense of larger upfront payments. Companies are now facing an interesting dilemma. Suppose a company has a lead product candidate ready for Phase II clinical testing. One
Today we hear the news that Covance has done it again. Today they acquired two European R&D sites from Sanofi for $25 million. In addition, Sanofi agreed to purchase R&D services from these facilities for up to $2.2 billion over 10 years. This follows a similar deal struck with Lilly in the US in 2008.